Immix Biopharma, Inc.(IMMX)Earnings, Financials & Key RatiosImmix Biopharma, Inc. (IMMX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the $79.3 million cash position provides a near-term liquidity buffer, the accelerating quarterly burn rate of over $10 million warrants caution regarding the long-term funding requirements for the NXC-201 program.
Immix Biopharma, Inc. (IMMX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Immix Biopharma, Inc. (IMMX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.18vs $0.18+0.3% | — |
| Q2 2026 | Mar 25, 2026 | $0.27vs $0.21-28.6% | — |
| Q4 2025 | Nov 7, 2025 | $0.24vs $0.19-26.3% | — |
| Q3 2025 | Aug 8, 2025 | $0.22vs $0.21-4.8% | — |
Recent stock market news and headlines for Immix Biopharma, Inc. (IMMX)
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.
The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Key metrics vs top competitors for Immix Biopharma, Inc. (IMMX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.02 | $654.03M | -13.51 | — | — | -55% | — | |
| $3.10 | $505.47M | -1.89 | — | — | -131.58% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
Immix Biopharma, Inc. (IMMX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Immix Biopharma, Inc. (IMMX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 21, 2026·SEC
May 21, 2026·SEC
Mar 30, 2026·SEC
Get notified when IMMX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Immix Biopharma, Inc. (IMMX) stock FAQ — growth, dividends, profitability & financials explained
Immix Biopharma, Inc. (IMMX) reported a net loss of $35.0M for fiscal year 2025.
Immix Biopharma, Inc. (IMMX) has a return on equity (ROE) of -55.0%. Negative ROE indicates the company is unprofitable.
Immix Biopharma, Inc. (IMMX) had negative free cash flow of $32.8M in fiscal year 2025, likely due to heavy capital investments.
